4.7 Article

Use of Antistaphylococcal β-Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding

期刊

CLINICAL INFECTIOUS DISEASES
卷 53, 期 2, 页码 158-163

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir340

关键词

-

资金

  1. Sharp Healthcare Foundation
  2. Cubist Pharmaceuticals
  3. Astellas Pharmaceuticals
  4. Cubist
  5. Pfizer Pharmaceuticals
  6. Astellas
  7. Ortho-McNeil Pharmaceuticals

向作者/读者索取更多资源

We used daptomycin plus antistaphylococcal beta-lactams (ASBL) to clear refractory MRSA bacteremia. In vitro studies showed enhanced daptomycin bactericidal activity, increased membrane daptomycin binding, and decrease in positive surface charge induced by ASBLs against daptomycin nonsusceptible MRSA. Addition of ASBLs to daptomycin may be of benefit in refractory MRSA bacteremia. (Although the official designation is daptomycin nonsusceptiblity, we will use the term daptomycin-resistance in this paper for facility of presentation.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据